Clinical Trial Update: Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD [Phase 2]

View source ↗

Summary

Phase 2 dose-finding study evaluating a new formulation of tolvaptan in adults with autosomal dominant polycystic kidney disease; results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• tolvaptan (tolvaptan)

Snippet

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. | Conditions: Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Status: COMPLETED | Results posted: 2018-06-14